Literature DB >> 1310734

Decreases in unintegrated HIV DNA are associated with antiretroviral therapy in AIDS patients.

R E Dickover1, R M Donovan, E Goldstein, S H Cohen, V Bolton, R G Huth, G Z Liu, J R Carlson.   

Abstract

Better markers are needed to monitor the efficacy of antiretroviral drugs in persons infected with human immunodeficiency virus (HIV). We investigated the effects of zidovudine (ZDV) and dideoxycytidine (ddC) on the presence of unintegrated HIV-1 DNA in peripheral blood mononuclear cells (PBMCs) from AIDS patients. DNA was extracted from PBMCs and separated into low molecular weight (unintegrated) and high molecular weight (integrated) chromosomal fractions. These DNA fractions were then amplified by a quantitative polymerase chain reaction (PCR) and the amount and percentage of unintegrated HIV DNA were determined. Very high levels of unintegrated HIV DNA were found in AIDS patients not receiving treatment with ZDV or ddC (median = 95% unintegrated HIV DNA). In contrast, most patients who had received 4 or more weeks of antiretroviral therapy had lower levels of unintegrated HIV DNA (median = 30% unintegrated HIV DNA for patients receiving ZDV). Paired samples taken from five patients before and after therapy showed a striking reduction in the percentage of unintegrated HIV DNA. The decrease in the proportion of unintegrated HIV DNA in AIDS patients was due to both a reduction in the copy number of unintegrated HIV DNA and an increase in the copy number of integrated HIV DNA. Thus, measurements of unintegrated and integrated HIV DNA may be useful in providing objective assessments of the effectiveness of antiretroviral therapies.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1310734

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr (1988)        ISSN: 0894-9255


  12 in total

1.  Regional cortical thinning associated with detectable levels of HIV DNA.

Authors:  Kalpana J Kallianpur; Gregory R Kirk; Napapon Sailasuta; Victor Valcour; Bruce Shiramizu; Beau K Nakamoto; Cecilia Shikuma
Journal:  Cereb Cortex       Date:  2011-10-19       Impact factor: 5.357

Review 2.  Zidovudine: a review of pharmacoeconomic and quality-of-life considerations for its use in patients with human immunodeficiency virus.

Authors:  H D Langtry; K J Palmer; P Benfield
Journal:  Pharmacoeconomics       Date:  1993-04       Impact factor: 4.981

3.  High susceptibility of U937-derived subclones to human immunodeficiency virus type 1 infection correlates with accumulation of unintegrated circular viral DNA.

Authors:  M Kameoka; T Kimura; Y Okada; K Fujinaga; T Nakaya; H Takahashi; M Kishi; K Ikuta
Journal:  Virus Genes       Date:  1996       Impact factor: 2.332

4.  BAL fluid analysis and HIV-1 infection.

Authors:  J R Clarke; J D Williamson; D M Mitchell
Journal:  Thorax       Date:  1995-06       Impact factor: 9.139

5.  HIV-1 proviral DNA copy number in peripheral blood leucocytes and bronchoalveolar lavage cells of AIDS patients.

Authors:  J R Clarke; A J Gates; R J Coker; J A Douglass; J D Williamson; D M Mitchell
Journal:  Clin Exp Immunol       Date:  1994-05       Impact factor: 4.330

6.  Concurrent measures of total and integrated HIV DNA monitor reservoirs and ongoing replication in eradication trials.

Authors:  Angela M Mexas; Erin H Graf; Matthew J Pace; Jianqing J Yu; Emmanouil Papasavvas; Livio Azzoni; Michael P Busch; Michele Di Mascio; Andrea S Foulkes; Stephen A Migueles; Luis J Montaner; Una O'Doherty
Journal:  AIDS       Date:  2012-11-28       Impact factor: 4.177

7.  Amount of HIV DNA in peripheral blood mononuclear cells is proportional to the severity of HIV-1-associated neurocognitive disorders.

Authors:  Bruce Shiramizu; Andrew E Williams; Cecilia Shikuma; Victor Valcour
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2009       Impact factor: 2.198

8.  Effect of 2',3'-didehydro-3'-deoxythymidine in an in vitro hollow-fiber pharmacodynamic model system correlates with results of dose-ranging clinical studies.

Authors:  J A Bilello; G Bauer; M N Dudley; G A Cole; G L Drusano
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191

Review 9.  Zalcitabine. A review of its pharmacology and clinical potential in acquired immunodeficiency syndrome (AIDS).

Authors:  R Whittington; R N Brogden
Journal:  Drugs       Date:  1992-10       Impact factor: 9.546

10.  Efficacy of constant infusion of A-77003, an inhibitor of the human immunodeficiency virus type 1 (HIV-1) protease, in limiting acute HIV-1 infection in vitro.

Authors:  J A Bilello; P A Bilello; J J Kort; M N Dudley; J Leonard; G L Drusano
Journal:  Antimicrob Agents Chemother       Date:  1995-11       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.